Glaukos Corporation’s (GKOS) Buy Rating Reiterated at BMO Capital Markets
BMO Capital Markets reaffirmed their buy rating on shares of Glaukos Corporation (NYSE:GKOS) in a report published on Friday. The firm currently has a $54.00 price target on the medical instruments supplier’s stock.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Glaukos Corporation from a hold rating to a buy rating and set a $41.00 price objective for the company in a research note on Friday, August 4th. BidaskClub downgraded shares of Glaukos Corporation from a hold rating to a sell rating in a research note on Saturday, August 5th. Roth Capital reduced their price objective on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating for the company in a research note on Thursday, August 3rd. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $54.00 price objective on shares of Glaukos Corporation in a research note on Thursday, May 4th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $52.33.
Shares of Glaukos Corporation (GKOS) opened at 37.83 on Friday. The company has a 50 day moving average price of $38.52 and a 200 day moving average price of $42.69. The stock’s market cap is $1.30 billion. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.
TRADEMARK VIOLATION NOTICE: “Glaukos Corporation’s (GKOS) Buy Rating Reiterated at BMO Capital Markets” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/04/glaukos-corporations-gkos-buy-rating-reiterated-at-bmo-capital-markets.html.
In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 325,000 shares of Glaukos Corporation stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 16.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GKOS. Teachers Advisors LLC grew its holdings in Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after purchasing an additional 1,506 shares during the last quarter. Bank of Montreal Can purchased a new position in Glaukos Corporation in the first quarter worth $3,196,000. Nationwide Fund Advisors grew its holdings in Glaukos Corporation by 749.3% in the first quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock worth $4,571,000 after purchasing an additional 78,610 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp purchased a new position in Glaukos Corporation in the first quarter worth $776,000. Finally, Wells Fargo & Company MN grew its holdings in Glaukos Corporation by 73.2% in the first quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock worth $59,332,000 after purchasing an additional 488,730 shares during the last quarter.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.